Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tavapadon · Juvmo, CVL-751

Small molecule · developed by Abbvie

Approved FDA, Sep 2026
ABBV Developer
1 Registered trials

What is Tavapadon?

Tavapadon (CVL-751) is a small molecule that acts as a dopamine receptor agonist. It is being studied in Parkinson disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Juvmo, CVL-751
Drug type
Small molecule
Therapy area
Neurology
Developer
Abbvie (ABBV)
FDA status
Approved as Juvmo (September 25, 2026), NDA220415
UNII
PT4P8MJP8L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07158827 N/A Parkinson Disease No longer available ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Parkinson Disease

More from Abbvie

Follow ABBV, the company behind Tavapadon

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.